Eli Lilly and Company LLY is a key player in the diabetes and obesity drug market, mainly due to the significant popularity ...

Over the past year, Eli Lilly ($LLY) stock has tumbled almost 24%, pressured by regulatory concerns, disappointing trial ...

Through innovation, cost discipline, legal action, and competitive pricing, Novo Nordisk has reasserted its leadership in the GLP-1 market. With a robust pipeline and global expansion, NVO is poised ...

Eli Lilly's Mounjaro and Zepbound drove Q2 2025 revenue up 38% and EPS up 92% YoY. Read why LLY stock's recent 20% pullback ...

This medicine generated $3.6 billion in sales last year. But according to some estimates, the oral GLP-1 market could hit $20 ...

Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors ...

Eli Lilly (LLY) is falling today due to reports of progress from competitors. The pharmaceutical producer has struggled recently as its share of the obesity treatment pill market has been threatened.

In the wake of this sell-off, a critical question arises about whether LLY stock represents a buying opportunity.

Eli Lilly and Co (NYSE: LLY) has entered into a $1.3 billion deal with Superluminal Medicines to develop small-molecule drugs ...

Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) fell 13.9% in the afternoon session after its oral weight-loss drug trial results disappointed investors, overshadowing an otherwise strong ...

Eli Lilly (LLY) has outperformed the S&P index and its competitors during the past 5 years, LLY has a broad product portfolio, a robust pipeline that is built to power market performance.